Articles published by Junshi Biosciences

< Previous 1 2 Next >

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

January 09, 2024

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients

January 02, 2024

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA

December 01, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

November 22, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023

October 27, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates

August 30, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer

July 19, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

July 11, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

June 29, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer

May 23, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries

May 07, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

April 27, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study

April 20, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

April 11, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients

April 11, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates

March 31, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia

March 28, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies

February 27, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study

February 20, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

February 15, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Approval for Marketing of VV116 in China

January 30, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Acceptance of NDA for VV116 in China

January 17, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study

January 17, 2023

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19

December 29, 2022

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

December 26, 2022

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

December 25, 2022

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

December 10, 2022

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

November 24, 2022

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection

November 22, 2022

From Junshi Biosciences

Via GlobeNewswire

Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab

November 14, 2022

From Junshi Biosciences

Via GlobeNewswire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.